NICECACTUS/GLORY4GAMERS
26.2.2020 14:02:11 CET | Business Wire | Press release
Following the announcement of an initial funding round of €5 million at the end of 2019, Nicecactus has taken yet another step forward in its global development by acquiring Glory4Gamers. The strategic alliance of these two esports experts provides 1 million users with an all-in-one solution, combining knowledge in training and skill development as well as in organizing both online and offline tournaments. Players, partners and B2B customers alike can now benefit from the comprehensive range of services of these two stakeholders.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200226005081/en/
Since the end of January 2020, Nicecactus and Glory4Gamers have combined their expertise and solutions with the ambition to further expand internationally. The G4G teams have joined the Nicecactus family to form a 70-person team. They are reinforcing the already successful model of tournaments and competitions with prize money for players of all levels. In addition, the offline B2B event package, which enables brands (sponsors and publishers) to run promotional campaigns among qualified audiences, will be developed to become one of the pillars of the Nicecactus offer.
An all-in-one platform for aspiring champions
Amateur or semi-professional players, members of the Glory4Gamers and nicecactus.gg platforms, will now benefit from a complete solution empowering them with the professional training method they need to reach their full potential and realize their dream of becoming champions. It ranges from tailor-made training sessions (tutorials and drills), to performance assessment and analysis tools, as well as daily competitions with prizes and even networking with professional players in the sector (sponsors, teams) for the most talented of them.
All players are also eligible for the Nicecactus Grassroots Esports Fund, a $1 million grant program, through which they can cover travel and accommodation expenses to participate in bootcamps at professional training locations or tournaments they have qualified for.
“The decision to acquire Glory4Gamers fits perfectly with our strategy to develop and strengthen our unique offer, which encompasses virtually all aspects of esports, from amateurs to semi-professional players, as well as companies wishing to address this highly qualified target audience,” explains Mike Hessabi, Founder & President of Nicecactus.
"The esports market is growing at breakneck speed, and we want more than ever to be at the heart of this ecosystem. Nicecactus approaches esports with an innovative vision and great ambitions. The combination of Glory4Gamers and Nicecactus felt obvious to us, as we have a very aligned vision and complementary skills," adds Cyril Chomette, CEO and Founder of Glory4Gamers.
About Nicecactus:
First ever all-encompassing esports platform, Nicecactus took root in the sun-bathed French Riviera. Its goal is to foster aspiring esports players who wish to unleash their gaming potential and master their game. Nicecactus provides them with a professional training method as well as all the tools they need to fulfill their dream of becoming champions. Players from all over the world are encouraged to give the best out of themselves, through a continued training program, a fined-tuned stats tracking system and the opportunity to compete in tournaments and make some cash out of their passion in a challenging and fun way. Its first-of-its-kind Nicecactus Grassroots Esports Fund rewards the best players for their talent and dedication by connecting them to the professional world. www.nicecactus.gg
About Glory4Gamers:
Founded in 2012, Glory4Gamers is a pioneer in amateur esports. Now the leading organizer of esports tournaments in France and 3rd in Europe, the platform holds more than 2,000 tournaments per month. Through its unique real-time refereeing component, Glory4Gamers promises its users a unique esports experience, in a fun and fair play environment, and with a human support close at hand.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200226005081/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom